SI3694863T1 - Kristalna oblika hidrata proste baze lorlatiniba - Google Patents
Kristalna oblika hidrata proste baze lorlatinibaInfo
- Publication number
- SI3694863T1 SI3694863T1 SI201830952T SI201830952T SI3694863T1 SI 3694863 T1 SI3694863 T1 SI 3694863T1 SI 201830952 T SI201830952 T SI 201830952T SI 201830952 T SI201830952 T SI 201830952T SI 3694863 T1 SI3694863 T1 SI 3694863T1
- Authority
- SI
- Slovenia
- Prior art keywords
- free base
- crystalline form
- base hydrate
- lorlatinib free
- lorlatinib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762570326P | 2017-10-10 | 2017-10-10 | |
US201862727734P | 2018-09-06 | 2018-09-06 | |
EP18795807.9A EP3694863B1 (en) | 2017-10-10 | 2018-10-04 | Crystalline form of lorlatinib free base hydrate |
PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3694863T1 true SI3694863T1 (sl) | 2023-10-30 |
Family
ID=64049474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201830952T SI3694863T1 (sl) | 2017-10-10 | 2018-10-04 | Kristalna oblika hidrata proste baze lorlatiniba |
Country Status (22)
Country | Link |
---|---|
US (1) | US11299500B2 (sl) |
EP (1) | EP3694863B1 (sl) |
JP (1) | JP7153069B2 (sl) |
KR (1) | KR102424621B1 (sl) |
CN (1) | CN111201235B (sl) |
AU (1) | AU2018349259B2 (sl) |
BR (1) | BR112020005989A2 (sl) |
CA (1) | CA3077508C (sl) |
CY (1) | CY1126141T1 (sl) |
DK (1) | DK3694863T3 (sl) |
ES (1) | ES2952985T3 (sl) |
FI (1) | FI3694863T3 (sl) |
HU (1) | HUE062926T2 (sl) |
MX (1) | MX2020003373A (sl) |
PL (1) | PL3694863T3 (sl) |
PT (1) | PT3694863T (sl) |
RU (2) | RU2020113141A (sl) |
SG (1) | SG11202002445SA (sl) |
SI (1) | SI3694863T1 (sl) |
TW (1) | TWI775960B (sl) |
WO (1) | WO2019073347A1 (sl) |
ZA (1) | ZA202001661B (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3798222T3 (pl) | 2015-07-31 | 2024-03-25 | Pfizer Inc. | Krystaliczna postać wolnej zasady lorlatynibu |
US11078215B2 (en) | 2016-04-08 | 2021-08-03 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
US20210163498A1 (en) * | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
EP3999514A1 (en) * | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
RS56972B1 (sr) * | 2011-06-08 | 2018-05-31 | Biogen Ma Inc | Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata |
EP2822953B9 (en) * | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
JP6609308B2 (ja) * | 2014-08-20 | 2019-11-20 | テリジーン リミテッド | キナーゼ阻害剤としての置換マクロサイクル |
PL3798222T3 (pl) * | 2015-07-31 | 2024-03-25 | Pfizer Inc. | Krystaliczna postać wolnej zasady lorlatynibu |
US11078215B2 (en) | 2016-04-08 | 2021-08-03 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 RU RU2020113141A patent/RU2020113141A/ru unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en unknown
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 BR BR112020005989-7A patent/BR112020005989A2/pt active Search and Examination
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active IP Right Grant
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
TW201922753A (zh) | 2019-06-16 |
BR112020005989A2 (pt) | 2020-09-29 |
KR20200051781A (ko) | 2020-05-13 |
CA3077508C (en) | 2023-02-14 |
HUE062926T2 (hu) | 2023-12-28 |
CY1126141T1 (el) | 2023-11-15 |
CN111201235A (zh) | 2020-05-26 |
US20200308191A1 (en) | 2020-10-01 |
PL3694863T3 (pl) | 2023-09-25 |
RU2020113141A3 (sl) | 2021-11-12 |
EP3694863B1 (en) | 2023-06-21 |
CA3077508A1 (en) | 2019-04-18 |
PT3694863T (pt) | 2023-08-23 |
AU2018349259B2 (en) | 2021-02-18 |
US11299500B2 (en) | 2022-04-12 |
TWI775960B (zh) | 2022-09-01 |
ZA202001661B (en) | 2023-11-29 |
DK3694863T3 (da) | 2023-07-03 |
JP7153069B2 (ja) | 2022-10-13 |
CN111201235B (zh) | 2023-02-10 |
AU2018349259A1 (en) | 2020-04-09 |
KR102424621B1 (ko) | 2022-07-25 |
RU2022109286A (ru) | 2022-05-06 |
EP3694863A1 (en) | 2020-08-19 |
MX2020003373A (es) | 2020-10-12 |
WO2019073347A1 (en) | 2019-04-18 |
ES2952985T3 (es) | 2023-11-07 |
RU2020113141A (ru) | 2021-11-12 |
SG11202002445SA (en) | 2020-04-29 |
FI3694863T3 (fi) | 2023-08-18 |
JP2020536893A (ja) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288519A (en) | inhibitors of ret | |
SG11202002445SA (en) | Crystalline form of lorlatinib free base hydrate | |
HK1252845A1 (zh) | 勞拉替尼游離碱的結晶形式 | |
SG10202111790YA (en) | Synthesis of omecamtiv mecarbil | |
PT3577125T (pt) | Formas cristalinas de tenofovir alafenamida | |
IL272697A (en) | A polymorphic form of TG02 | |
SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
GB201614939D0 (en) | Crystalline hydrate | |
HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
SI3529236T1 (sl) | Kristalinične oblike eravaciklina | |
PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
IL253479A0 (en) | Crystalline forms of efinconazole | |
IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
IL269792B (en) | Crystalline forms of (s)–apoxolner | |
IL270937A (en) | Crystalline forms of saltalicib |